Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...

On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion.

Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

This was the stock's second consecutive day of losses.